TP53 mutations in triple-negative breast cancer cells confer sensitivity to ASCT2 inhibition via arginine uptake
Xiaodan Lyu, Yuancheng Wei, Ziyi Chen, Qianlin Zou, Jia Wang, Yi Han, Chenxi Xu, Haolin Hu, Zizhang Zhou, Shengtao Yuan, Mei Yang, Li Sun · 2026
Read TP53 mutations in triple-negative breast cancer cells confer sensitivity to ASCT2 inhibition via arginine uptake by Xiaodan Lyu, Yuancheng Wei, Ziyi Chen, Qianlin Zou, Jia Wang, Yi Han, Chenxi Xu, Haolin Hu, Zizhang Zhou, Shengtao Yuan, Mei Yang, Li Sun (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13365229.txt.
Description
Xiaodan Lyu and co-authors present a study the catalog lists under 2026. Triple-negative breast cancer lacks the usual drug targets and leans on altered fuel use. One fuel gate is ASCT2, a transporter feeding cells glutamine. Blocking it helps some tumors, but mixed responses and missing markers block clinical use. The team tests the blocker across breast cancer subtypes in dishes and animals. Gene and chemistry profiles trace how cells compensate.
Cancers carrying TP53 mutations prove most sensitive to the block. The reason runs through arginine uptake, a backup fuel route that mutant cells lean on. Oncologists get a genetic marker for a metabolism drug: the commonest mutation in this cancer type. Marker-led enrollment could rescue a drug class stalled by mixed trial results. Mapping the backup routes also previews resistance and the combinations that might preempt it.
Catalog record
| CREATOR | Xiaodan Lyu, Yuancheng Wei, Ziyi Chen, Qianlin Zou, Jia Wang, Yi Han, Chenxi Xu, Haolin Hu, Zizhang Zhou, Shengtao Yuan, Mei Yang, Li Sun |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |